On October 31, 2022 Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical needs, reported that AbbVie communicated during their third-quarter financial results1 on Friday October 28th, that they decided to stop the development of cedirogant (ABBV-157), an oral RORg inverse agonist jointly discovered by Inventiva and AbbVie for the treatment of autoimmune diseases, following the analysis of a recently concluded nonclinical toxicology study (Press release, Inventiva Pharma, OCT 31, 2022, View Source [SID1234622663]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Company’s cash runway, including the expected $12 million upfront payment from Sino Biopharm and the €25 million from the EIB credit facility2, is not impacted by the discontinuation of the cedirogant clinical program and should allow to fund as previously announced operations through Q4 20233. Inventiva’s R&D capabilities and objectives remain unaltered.
Frédéric Cren, Chairman, Chief Executive Officer and cofounder of Inventiva, stated: "Although we are disappointed to see the end of cedirogant’s clinical program following the analysis of a nonclinical toxicology study, we wish to thank our partner AbbVie for 10 years of collaboration. We are now fully focused on the development of our lead asset lanifibranor, a promising treatment which is currently in Phase III clinical development for the treatment of NASH, a disease for which there are currently no treatments approved by regulatory agencies. We continue to make progress in our NATiV3 pivotal Phase III trial and we recently reached a major milestone in this respect by entering into a partnership with Sino Biopharm, a leading Chinese pharmaceutical group, to develop and potentially commercialize lanifibranor in Greater China."
In 2012, Inventiva and AbbVie signed a multi-year drug discovery collaboration agreement to identify potent RORg inverse agonists for the treatment of several autoimmune diseases. Inventiva’s and AbbVie’s joint efforts led to the discovery of cedirogant, which was being evaluated in a Phase II clinical trial at the time of AbbVie’s decision to discontinue further clinical development.